23andMe is a consumer genetics and research company offering direct-to-consumer DNA testing for ancestry insights and health-related genetic reports. It combines large-scale genotyping, statistical genetics, and digital engagement to generate a unique database of consented genetic and phenotypic information. The company also leverages this data to drive therapeutics discovery and partnerships in biopharma and precision medicine.
Think of every patient as a unique garden: their genes are the soil, epigenetics is how the soil has been treated over time (fertilizer, pollution, stress), and the microbiome is the mix of plants and microbes living there. This work is about using data and models to understand how all three together affect health and how people respond to medicines, so treatments can be tailored to each person’s “garden” instead of using one-size-fits-all drugs.
Think of these biotechs as ‘AI-powered discovery engines’ for new medicines: instead of scientists testing millions of molecules one by one in a lab, they use advanced algorithms to search, simulate, and shortlist the most promising drug candidates before expensive experiments begin.